Subscribe
shutterstock-12540832
Eric Gevaert / Shutterstock.com
30 May 2014AmericasNabeela Rasheed

Dolly the sheep: the demise of biotechnology patents

The US Federal Circuit has recently been called upon to apply the Prometheus and Myriad decisions to a particularly famous project: the creation of Dolly the cloned sheep.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
UK Budget: A missed opportunity?